List of recent papers and grants (since 2017)

Selected Papers from 2017

Buckley AM, Lynam-Lennon N, Kennedy S, Dunne M, Aird J, Foley E, Clarke N, O’Toole D, Reynolds JV, Kennedy B and O’Sullivan J. Leukaemia inhibitory factor is associated with treatment resistance in Oesophageal Adenocarcinoma. Oncotarget (In Press).

O’Neill LA, Guinan E, Doyle SL, Bennett AE, Murphy C, Elliott JA, O’Sullivan J, Reynolds JV and Hussey J. The RESTORE randomised controlled trial: impact of a multidisciplinary rehabilitative program on cardiorespiratory fitness in Esophagogastric cancer survivorship. Ann Surgey Jul 12 2018.

Slater K, Hoo PS, Buckley AM, Piulats JM, Villanueva A, Portela, Kennedy BN. Evaluation of oncogenic cysteinyl leukotriene 2 as a therapeutic target for uveal melanoma. Cancer and Metastasis Reviews Aug 2018.

O’Sullivan K.E, Michielsen AJ, O’Regan E, Cathcart MC, Moore G, Breen E, Segurado R, Reynolds JV, Lysaght J and O’Sullivan J. pSTAT3 levels have divergent expression patterns and associations with survival in squamous cell carcinoma and adenocarcinoma of the oesophagus. International Journal of Medical Sciences June 10, 19 (6).

Bennett A, O’Neill L, Connolly D, Guinan E, Boland L, Doyle S.L, O’Sullivan J, Reynolds JV and Hussey J. Patient experiences of a physiotherapy-led multidisciplinary rehabilitation intervention after successful treatment for oesophago-gastric cancer. Supportive Cancer Care Aug 26 (8) 2615-2623.
Matchett KB, Lynam-Lennon N, Watson RW, Brown JAL. Advances in Precision Medicine: Tailoring Individualized Therapies. Cancers (Basel). 2017 Oct 25; 9(11).

Noonan S.A, Morrissey M.E, Martin P, Biniecka M, O’Meachair S, Maguire A, Tosetto M, Nolan B, Hyland J, Sheahan K, O’Donoghue D, Mulchay H, Fennelly D, O’Sullivan J. Tumour vasculature immaturity, oxidative damage and systemic inflammation stratifies survival of colorectal cancer patients on bevacizumab treatment. Oncotarget 2018, Feb 13 9 (12) 10536-10548.

Shrotriya S, Walsh D, Nowacki A, Lorton C, Aktas A, Hullihen B, Benanni-Baiti N, Hauser K, Ayvaz S, Estfan B. Serum C reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. Plos one Aug 23rd 2018.

Dunne PJ, Maher CO, Freeley M, Petrasca A, Orikiiriza J, Dunne MR, Reidy D, O'Dea S, Loy A, Woo J, Long A, Rogers TR, Mulcahy F, Doherty DG. CD3ε expression defines functionally-distinct subsets of Vδ1 T cells in patients with HIV infection. PMID: 29770136

Guinan E, Doyle SL, Bennett A, O’Neill L, Gannon J, Elliott JA, O’Sullivan J, Reynolds JV and Hussey E. Sarcopenia during Neoadjuvant Therapy for Oesophageal Cancer: Characterising the impact on muscle strength and physical performance. Supportive Care in Cancer May 2018 26 (5) 1569-1576.

2017. Dowling CM, Hayes SL, Phelan JJ, Cathcart M, Finn SP, Mehigan B, McCormick P, Coffey JC, O’Sullivan J and Kiely P. Expression of protein kinase C gamma promotes cell migration in colon cancer.  Oncotarget 2017 July 1st.

O’Neill L, Doyle SL, Guinan E, O’Sullivan J, Reynolds JV and Hussey J. Rehabilitation strategies following esophageal cancer-the ReStOre trial, a feasibility study. Dis Esophagus (In Press). 

Prichard D, Byrne A, O’ Murphy J , Reynolds JV, O'Sullivan J , Feighery R , Doyle B, Eldin O, Finn S,  Maguire A,  Duff D, Kelleher D,  Long A. Deoxycholic acid modulates oesophageal squamous cell adhesion through an integrin-mediated mechanism; implications for erosive gastro-oesophageal reflux disease and Barrett's oesophagus. Journal of Cell and Molecular Medicine 2017 Sep 22.

Dunne MR, Michielsen AJ, O’Sullivan KE, Cathcart MC, Feighery R, Doyle B, Watson JA, O’Farrell NJ, Ravi N, Kay E, Reynolds JV, Ryan EJ and O’Sullivan J. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma. Cancer Immunology Immunotherapy 2017 Mar 18.

Butler CT, Reynolds AL, Tosetto M, Dillion ET, Guiry P, Cagney G, O’Sullivan J and Kennedy BN. A Quininib Analogue and Cysteinyl Leukotreine Receptor Antagonist Inhibits VEGF-Independent Angiogenesis and Exerts an Additive Anti-angiogenic Response with Bevacizumab. J Biol Chem. 2017 Mar 3;292(9):3552-3567.

Conroy MJ, Maher SG, Melo AM, Doyle SL, Foley E, Reynolds JV, Long A, Lysaght J. Identifying a novel role for fractalkine (CX3CL1) in memory CD8+ T cell accumulation in the omentum of obesity-associated cancer patients. Front Oncol. 2018;9:1867.

Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O’Byrne KJ, Gately K. Development a characterization of a panel of PI3K-mTOR inhibitor resistant lung cancer cell lines. Sci Rep. 2018;8:1652.

Moody HL, Lind MJ, Maher SG. MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma. Mol Ther Nucleic Acids. 2017;8:317-329.

Lynam-Lennon N, Heavey S, Sommerville G, Bibby BA, Ffrench B, Quinn J, Gasch C, O’Leary JJ, Gallagher MF, Reynolds JV, Maher SG. MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype. Oncotarget. 2017;8:11400-11413.

Ashanty M. Melo, Lei Zhang, Eilis F. Dockry, Andreea Petrasca, Yasmeen G. Ghnewa, Maria E. Morrissey, Ciara O’Reilly, Robin Bruen, Andrew O’Meara, Joanne Lysaght, Xiangming Zhu, Derek G. Doherty. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells. Glycobiology. 2018 Apr 6

Das B, Conroy M, Moore D, Lysaght J, McCrory C. Human Dorsal Root Ganglion Pulsed Radiofrequency treatment modulates Cerebrospinal Fluid lymphocytes and  neuroinflammatory markers in chronic radicular pain. Brain Behav Immun. 2018 Feb 16.

Galvin KC, Conroy MJ, Doyle SL, Dunne MR, Fahey R, Foley E, O'Sullivan KE, Doherty DG, Geoghegan JG, Ravi N, O'Farrelly C, Reynolds JV, Lysaght J. Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma. Cancer Lett. 2018 Jan 12.

Doyle SL, Mongan AM, Donohoe CL, Pidgeon GP, Sherlock M, Reynolds JV, Lysaght J. Impact of visceral obesity and metabolic syndrome on the postoperative immune, inflammatory, and endocrine response following surgery for esophageal adenocarcinoma. Dis Esophagus. 2017 Jun 1;30(6):1-11.

New Grants awarded since 2017

Health Research Board/MRCG Breakthrough Cancer 2019-2022: Gold-drug: Targeting a novel dual inhibitor drug with gold nanoparticles for improving radiation response in oesophageal cancer. €288,570. PI: Prof Jacintha O’Sullivan

Irish Research Council 2017-2020: Elucidation the therapeutic importance of the radiation-induced bystander effect (RIBE) in rectal cancer patients. €72,000. Scholar: Ms. Aisling Heeran. PI: Prof. Jacntha O’Sullivan and Dr. Niamh Lynam Lennon
Science Foundation Ireland/Technology Innovation Development Award. 2017. Pre-clinical evaluation of CC12, a novel anti-angiogenic drug, as a combination therapy for colorectal cancer patients. €129,685 (€99,758 direct and €29,927 indirect costs). PI: Prof. Jacintha O’Sullivan

Meath Foundation research grants, 2018, “The use of ‘liquid biopsy’ in patients with pre-cancerous pancreatic cystic lesions”, €75K, co-applicant. Dr. Stephen Maher

TCD Provost’s PhD Project Award, 2018, “Understanding the role of microRNA-31 in the regulation of cellular sensitivity to chemoradiotherapy in pancreatic adenocarcinoma”, €85K, PI. Dr. Stephen Maher

SFI Opportunistic Fund, 2017, “Upgrade of the biological irradiator core at the TTMI”, €125K, PI.Dr. Stephen Maher.
TCD Dean’s Research and Innovation Award, 2017, “Development of a bioscaffold for in vivo delivery of radiosensitising microRNAs”, €20K, PI. Dr. Stephen Maher.

Wellcome Trust-HRB-SFI Institutional Strategic Support Fund, 2017, €30K, PI.Dr. Stephen Maher.
Kazan McClane Partners, 2017, “Understanding the role of microRNA-31 in regulating intracellular drug trafficking in MPM”, $25K, PI. Dr. Stephen Maher

Co-Principal Investigator: Irish Cancer Society Scholarship 2018 (Scholar: Rebecca O'Brien) Funding Agency: Irish Cancer Society Project Title: Investigation of the role of the complement cascade in the radioresistance of rectal cancer.  € 127,926.00 over 4 years PI’s. Dr. Niamh Lynam Lennon and Dr. Joanne Lysaght.

Trinity St. James’s Cancer Institute Cancer Immunology Stimulus Award 2017. Co-Principal Investigator Funder: Trinity St. James’s Cancer Institute Project Title: Unravelling the role of tumour-derived complement on natural killer cell function in the response of oesophageal adenocarcinoma to neoadjuvant chemoradiation therapy: € 5,000 over 1 year Dr. Niamh Lynam Lennon

Emerging Investigator Award 2017 Funding Agency: Health Research Board Project Title: Targeting metabolism for individualised rectal cancer treatment: Development of anomics-led predictive signature of chemoradiation therapy response and novel neoadjuvant therapeutic strategy. € 660,992.00 over 4 years. PI. Dr. Niamh Lynam Lennon

Investigator Led Projects 2017. Funding Agency: Health Research Board. Project Title: Prospective validation of the complement system as a novel treatment stratification tool in oesophageal adenocarcinoma patients. € 369,027.00 over 4 years. Dr. Niamh Lynam Lennon
October  2018: Irish Research Council Government of Ireland Scholarship Award. Role: PI. Enhancing anti-tumour immunity in Oesophageal cancer through the modulation of immunometabolism with the novel small molecule inhibitor Quininib and its analogues. Amount Awarded: 96,000 euro. PI. Dr. Joanne Lysaght.

April 2018: Health Research Board Investigator Lead Project: Role: PI. Elucidating the pathological role of obesity, inflammation and immunity in cancer related sarcopenia in upper gastrointestinal cancers. Amount Awarded: 336,592 euro. Dr. Joanne Lysaght.
SFI TIDA Award: Overcoming treatment resistance to chemoradiation therapy in oesophageal adenocarcinoma using a novel patented small molecule radiosensitiser drug, CC8.€90,967 in direct costs (€27,240 indirect). PI. Dr. Susan Kennedy.

December 2017: Cancer Immunology Stimulus Award. Role: Co-PI. Investigating the role of IL-36α in Barrett’s Oesophagus and Oesophageal Adenocarcinoma as a novel immunotherapeutic and immunopreventative agent. Amount Awarded: 10,000 euro. Dr. Joanne Lysaght.

December 2017: Health Research Board Knowledge Exchange and Dissemination Scheme (KEDS): Role: Co-applicant. Cracking the Mysteries of Cancer Immunotherapies-e.Courses For Oncology Healthcare Professionals Amount Awarded: 32,725.00 euro. Dr. Joanne Lysaght.

December 2017: Health Research Board Investigator Lead Project: Role: Co-applicant. Assessment of the predictive value of immune and histological parameters in oesophageal adenocarcinoma using digital pathology. Amount Awarded: 369,807 euro. Dr. Joanne Lysaght.

October 2017: Health Research Board Investigator Lead Project: Role: Co-applicant. Prospective validation of the complement system as a novel treatment stratification tool in oesophageal adenocarcinoma patients. Amount Awarded: 369,027 euro. Dr. Joanne Lysaght.

October  2017: Irish Research Council Government of Ireland Scholarship Award. Role: PI. Investigating the applicability of novel cancer immunotherapies in upper gastrointestinal cancers and the impact of concurrent combination chemotherapy. Amount Awarded: 96,000 euro. Dr. Joanne Lysaght.

Health Research Board 2017-2020. Assessment of the predictive value of immune and histological parameters in oesophageal adenocarcinoma using digital pathology. €369,807. PI. Dr. Margaret Dunne.